Bupivacaine 0.125% Versus Bupivacaine 0.25% in Superficial Cervical Plexus Block for Tympanomastoid Surgeries in Adults

Launched by CAIRO UNIVERSITY · Apr 19, 2024

Keywords

ClinConnect Summary

This clinical trial is studying the use of two different concentrations of bupivacaine, a medication that helps reduce pain, during tympanomastoid surgery, which is a procedure done on the ear. The trial aims to see if using a lower concentration of bupivacaine (0.125%) is just as effective as a higher concentration (0.25%) in providing pain relief, keeping the surgical area clear of blood, and ensuring the patient's overall stability during and after the surgery. This could potentially improve the experience for both the surgeon and the patient by making the surgery easier and more effective.

To participate in this trial, adults aged 21 to 70 who are scheduled for tympanomastoid surgery may be eligible. However, certain conditions may exclude someone from participating, such as having allergies to the medication, significant health issues, or infections at the injection site. Participants will be randomly assigned to receive either the lower or higher concentration of bupivacaine, and they can expect to be closely monitored for pain management and overall health throughout the surgical process. This is an important study that could help improve surgical techniques and patient comfort during ear surgeries.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. Adults between 21 - 70 years.
• • 2. Patients undergoing tympanomastoid surgery.
• • 3. Both genders.
• • 4. ASA physical class I and II.
• Exclusion Criteria:
• • 1. Patient refusal.
• • 2. Uncooperative patients.
• • 3. Allergy to the drug enrolled in the study.
• • 4. Anatomical abnormality at injection site.
• • 5. Infection at injection site.
• • 6. Bleeding disorders.
• • 7. ASA physical class III and IV patients.
• • 8. Patients having significant chronic diseases as: uncontrolled asthma, cardiovascular disorders (significant arrhythmias, severe valvular diseases, congenital heart diseases, ischemic heart disease, or cardiomyopathy).
• • 9. Renal impairment (creatinine level ≥ 2mg/dl), or uncompensated chronic liver disease.